Year: 2020

news_6

Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA® (burosumab) to Include Older Adolescents and Adults for the Treatment of X-Linked Hypophosphataemia (XLH)

XLH is a rare, life-long genetic disease that causes abnormalities in the bones, muscles and joints1,2,3 TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co.,...

news_6

  CSOP CSI 300 Index Daily (2X) Leveraged Product (ticker:7233.HK) and CSOP CSI 300 Index Daily (-1X) Inverse Product (ticker:7333.HK) to List on the HKEX

HONG KONG--(BUSINESS WIRE)--Hong Kong’s largest leveraged and inverse products (L&I products) issuer1, CSOP Asset Management Limited (“CSOP”) is proud to...